AI Drug Discovery for Pharma and Biotech

Drug discovery

229

papers

On emerging therapies

Overview

Cleidocranial dysplasia (CCD) is a rare autosomal dominant skeletal dysplasia caused by mutations in the RUNX2 gene. It primarily affects intramembranous ossification, leading to clavicular hypoplasia/aplasia, delayed closure of cranial sutures, dental anomalies (supernumerary/impacted teeth), and short stature. Craniofacial features include frontal bossing and midface hypoplasia. Systemic manifestations involve vertebral, pelvic, and digital abnormalities. Cognitive function is typically preserved [1][12][16][20].

Population

  • Prevalence: ~1:1,000,000 globally, with higher rates in founder populations [2][12][14].

  • Demographics: Equal sex distribution; reported across all ethnic groups [12][13][16].

Burden

  • Functional: Lifelong need for dental/oral surgeries and skeletal interventions [8][11][16].

  • Psychosocial: Disproportionate short stature and facial dysmorphism impacting self-esteem [1][5][20].

  • Comorbid: Increased risk of recurrent sinus/ear infections, osteoporosis, and obstetric complications (cephalopelvic disproportion) [9][12][16].

Therapies

  • Multidisciplinary care: Orthodontic-surgical interventions for dental impaction (supernumerary tooth removal, prosthodontics) [3][5][13].

  • Orthopedic management: Craniofacial reconstruction, spinal stabilization, and clavicular resection for brachial plexus compression [6][13][20].

  • Supportive measures: Calcium/vitamin D supplementation, protective helmets for open fontanelles, and infection prophylaxis [6][9][13].

Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare odontological diseases

Research Papers

229 drug discovery papers about Cleidocranial dysplasia. Recent publications:

229 drug discovery papers about Cleidocranial dysplasia. Recent publications:

categories:

Small molecules

small molecules
2026-09-17 | SCFJFK regulates osteoblast differentiation through targeting RUNX2.

RUNX2 (Runt-related transcription factor 2) is a master regulator of osteogenesis, and its genetic mutations are associated with ~65% cases of cleidocranial dysplasia (CCD), an autosomal dominant abnormal bone development disorder in humans with defective intramembranous bone formation. However, how these mutations affect bone formation remains to be investigated. Here, we report that RUNX2 interacts with the F-box protein JFK and is destabilized by the SKP1-CUL1-JFK E3 ubiquitin ligase complex (SCFJFK). We find that several CCD-associated mutations of RUNX2 acquire an increased affinity toward SCFJFK thus an accelerated proteasomal degradation. We demonstrate that SCFJFK-mediated RUNX2 degradation suppresses osteoblast differentiation. Consistently, Jfk-null mice exhibit increased trabecular bone volume and bone mineral density and are resistant to Runx2 haploinsufficiency-induced CCD-like syndrome. Interestingly, RUNX2 binds to the JFK promoter and represses its transcription, establishing a feedback loop to promote osteoblast differentiation, and remarkably, the CCD-associated RUNX2 mutants also display an impaired transcription repression of JFK. Our study demonstrates SCFJFK as an E3 ligase for RUNX2 and uncovers a feedback regulatory loop between SCFJFK and RUNX2 that is implemented in bone development and implicated in CCD, supporting the pursuit of JFK as a potential target to ameliorate CCD-like syndrome.

Open article ↗



2026-04-20 | Sost deficiency restores calvarial bone thickness without recovery of sutural growth in Runx2 missense mutant mice.

Runt-related transcription factor 2 (Runx2) is a key transcription factor essential for osteogenesis, and RUNX2 haploinsufficiency causes cleidocranial dysplasia, whereas sclerostin encoded by Sost negatively regulates bone mass by antagonizing Wnt/β-catenin signaling. Although the individual roles of Runx2 and sclerostin in skeletal biology have been extensively studied, their combined effects on calvarial development have not been directly examined in vivo. Here, we investigated whether Sost deficiency affects the cranial phenotype associated with Runx2 haploinsufficiency. Using skeletal preparations, micro-computed tomography, and three-dimensional morphometric analysis of the interparietal bone, we analyzed Sost-deficient, Runx2 missense mutant, and Runx2-Sost compound mutant mice at embryonic day 18.5 (E18.5) and postnatal day 90 (P90). At E18.5, both Runx2R232Q/R232Q;Sost+/+ and Runx2R232Q/R232Q;SostΔ26/Δ26 mice lacked ossification throughout the body. At P90, Runx2R232Q/+;Sost+/+ mice exhibited cranial hypoplasia with delayed suture closure. In Runx2R232Q/+;SostΔ26/Δ26 mice, interparietal bone thickness was restored to wild-type levels, whereas the bone volume showed only partial recovery. Bone volume/tissue volume and bone mineral density increased to levels higher than those of wild-type, comparable to those of Runx2+/+;SostΔ26/Δ26. However, the bone surface area exhibited no significant improvement, and delayed suture closure around the interparietal bone and anterior and posterior fontanelles persisted. Thus, Sost-deficiency augments postnatal calvarial mass primarily by thickening without expanding the surface area and does not normalize suture/fontanelle morphogenesis under Runx2 haploinsufficiency. Our findings reveal a differential genetic effect of Sost deficiency on calvarial thickness and sutural growth in mice with Runx2 haploinsufficiency.

Open article ↗



2026-01-01 | Clinical and genetic study on a cleidocranial dysplasia family

Objective To confirm the mutation in a family with cleidocranial dysplasia (CCD) and explore its possible effects on protein structure and function. Methods A proband with CCD was diagnosed through clinical symptoms and radiography examinations. Peripheral blood samples were collected from the proband and his family members for whole-exome sequencing. The pathogenic mutation was validated by Sanger sequencing. Further investigations were conducted to analyze the protein structural and functional changes induced by this mutation and explore the potential mechanisms by which this gene contributed to the pathogenesis of CCD. Results In this family, both the proband and his father exhibited typical clinical manifestations of cleidocranial dysplasia (CCD), including clavicular hypoplasia, delayed closure of fontanelles, craniofacial and dental abnormalities. A previously reported RUNX2 missense mutation (c. 569G>A, p. Arg190Gln) was identified in this family. This mutation occurred within the highly conserved runt domain, disrupting RUNX2 protein function. Bioinformatics analysis further confirmed the critical role of RUNX2 in craniofacial skeleton and tooth development. Conclusion A missense mutation in exon 4 of the RUNX2 gene is identified in a Chinese CCD family, providing novel therapeutic insights for CCD patients from molecular biological perspective.

Open article ↗



2025-12-27 | Functional impact of pathogenic mutations in the Runt homology domain of mouse Runx2 on skeletal and dental phenotypes in cleidocranial dysplasia.

Runt-related transcription factor 2 (RUNX2) is essential for skeletogenesis, and mutations in its gene cause cleidocranial dysplasia (CCD), an autosomal dominant skeletal disorder. The evolutionarily conserved 128-amino acid Runt homology domain (RHD) of human RUNX2 is essential for DNA binding and heterodimerization, and serves as a mutation hotspot associated with severe CCD phenotypes. To elucidate the functional impact of pathogenic RHD mutations in vivo, we generated two novel mouse lines: one carrying a missense mutation, c.695G>A, p.Arg232Gln (p.R232Q), corresponding to the human RUNX2 c.674G>A, p.Arg225Gln (p.R225Q), and the other harboring a frameshift mutation, c.697_698delGA, p.Glu233Thrfs*9 (p.E233Tfs*9), causing a premature stop codon. Homozygous Runx2R232Q/R232Q and Runx2E233Tfs*9/E233Tfs*9 mice lacked membranous ossification, whereas heterozygous Runx2R232Q/+ and Runx2E233Tfs*9/+ mice displayed typical CCD-like skeletal features, including an open anterior fontanelle and clavicle hypoplasia. Unexpectedly, heterozygotes carrying pathogenic RHD mutations developed small root-like protrusions, mostly one but rarely two, at the pulp chamber floor of three-rooted maxillary first molars during furcation, revealing a previously unrecognized dental phenotype. Dual luciferase assays showed that p.R232Q almost completely lost transactivation of the osteocalcin enhancer/promoter. Immunostaining showed that wild-type Runx2 was robustly expressed in osteoblasts and hypertrophic chondrocytes during bone formation, while the p.R232Q mutant Runx2 in Runx2R232Q/R232Q mice exhibited reduced expression in hypertrophic chondrocytes and partially impaired nuclear localization. These abnormalities led to defective osteoblast differentiation and chondrocyte maturation. Thus, our mutant mouse model provides a valuable in vivo platform to study CCD pathogenesis, mechanisms of tooth root furcation, and therapeutic interventions targeting dysfunctional RHD.

Open article ↗



2025-05-30 | RUNX2 is essential for maintaining synchondrosis chondrocytes and cranial base growth.

The cranial base synchondroses, comprised of opposite-facing bidirectional chondrocyte layers, drive anteroposterior cranial base growth. In humans, RUNX2 haploinsufficiency causes cleidocranial dysplasia associated with deficient midfacial growth. However, how RUNX2 regulates chondrocytes in the cranial base synchondroses remains unknown. To address this, we inactivated Runx2 in postnatal synchondrosis chondrocytes using a tamoxifen-inducible Fgfr3-creER (Fgfr3-Runx2cKO) mouse model. Fgfr3-Runx2cKO mice displayed skeletal dwarfism and reduced anteroposterior cranial base growth associated with premature synchondrosis ossification due to impaired chondrocyte proliferation, accelerated hypertrophy, apoptosis, and osteoclast-mediated cartilage resorption. Lineage tracing reveals that Runx2-deficient Fgfr3+ cells failed to differentiate into osteoblasts. Notably, Runx2-deficient chondrocytes showed an elevated level of FGFR3 and its downstream signaling components, pERK1/2 and SOX9, suggesting that RUNX2 downregulates FGFR3 in the synchondrosis. This study unveils a new role of Runx2 in cranial base chondrocytes, identifying a possible RUNX2-FGFR3-MAPK-SOX9 signaling axis that may control cranial base growth.

Open article ↗



gene therapies
2025-06-21 | Functional impact of pathogenic Runt domain mutations in Runx2 on skeletal and dental development in cleidocranial dysplasia

Abstract Runt-related transcription factor 2 (RUNX2) is essential for skeletogenesis, and mutations in its gene cause cleidocranial dysplasia (CCD), an autosomal dominant skeletal disorder. The evolutionarily conserved 128-amino acid Runt homology domain (RHD) of human RUNX2 is essential for DNA binding and heterodimerization, and serves as a mutation hotspot associated with severe CCD phenotypes. To elucidate the functional impact of pathogenic RHD mutations in vivo , we generated two novel mouse lines: one carrying a missense mutation, c.695G>A (p.R232Q) ( Runx2 m/+ ), corresponding to the human RUNX2 c.674G>A (p.R225Q), and the other harboring a frameshift mutation, c.697_698delGA (p.E233TfsTer9) ( Runx2 112/+ ), causing a premature stop codon. Homozygous Runx2 m/m and Runx2 112/112 mice lacked membranous ossification, whereas heterozygous Runx2 m/+ and Runx2 112/+ mice displayed typical CCD-like skeletal features, including an open anterior fontanelle and clavicle hypoplasia. Unexpectedly, heterozygotes carrying pathogenic mutations in RHD developed an accessory root-like protrusion at the furcation of three-rooted maxillary first molars, representing a previously unrecognized dental phenotype during root development. Dual luciferase assays revealed impaired transactivation of the p.R232Q mutant Runx2 on the osteocalcin enhancer/promoter. Wild-type Runx2 was robustly expressed in osteoblasts and hypertrophic chondrocytes during bone formation, but the mutant Runx2 exhibited reduced expression in hypertrophic chondrocytes and partially impaired nuclear localization, resulting in arrested osteoblast and chondrocyte maturation. Our mutant mouse model provides a valuable in vivo platform to study CCD pathogenesis, mechanisms of tooth root furcation, and therapeutic interventions targeting dysfunctional RHD.

Open article ↗



2025-04-10 | Downregulation of Nesprin1 by Runx2 deficiency is critical for the development of skeletal laminopathy-like pathology.

Runx2 is a master regulator of bone formation, and its dysfunction causes cleidocranial dysplasia (CCD) in humans. When iPS cells were generated from patients with CCD and Runx2-deficient iPS cells were generated using gene-editing techniques, abnormal laminopathy-like nuclei were observed. Runx2-deficient cells showed reduced Lamin A/C expression, but not protein levels. However, in Runx2-deficient cells, both the gene expression and protein levels of Nesprin1 were reduced, perinuclear actin fibers were sparser, and nuclear stiffness was reduced. Forced expression of Lamin A/C increased nuclear stiffness but did not improve nuclear morphology. In contrast, the induction of Nesprin1 expression alone normalized nuclear stiffness and restored nuclear morphology and perinuclear actin distribution. In Runx2-null cells, mechanical stress-induced phosphorylation of emerin was not observed. In contrast, forced expression of Nesprin1 in Runx2-null cells resulted in phosphorylation of emerin, indicating the restoration of intracellular tension. These observations were confirmed by atomic force microscopy. Therefore, the intracellular tension was inferred to pull the nuclear membrane into its normal shape. CUT&RUN assay and single RNA-seq analysis showed that an aberrant nuclear membrane caused loss of nuclear lamina gene regulation machinery, making the progression of normal osteogenic differentiation impossible; however, supplementation with Nesprin1 restored gene regulation mechanisms and promoted preosteoblast formation with normal nuclear morphology. Nesprin1 expression induced by Runx2 is essential for epigenetic regulation of the nuclear lamina. We propose CCD as a type of laminopathy involving defective expression of Nesprin1 regulated by Runx2.

Open article ↗



2024-12-04 | The impact of RUNX2 gene variants on cleidocranial dysplasia phenotype: a systematic review.

Cleidocranial Dysplasia (CCD) is a rare genetic disorder characterized by skeletal abnormalities and dental anomalies, primarily caused by variants in the RUNX2 gene. Understanding the spectrum of RUNX2 variants and their effects on CCD phenotypes is crucial for accurate diagnosis and management strategies. This systematic review aimed to comprehensively analyze the genotypic and phenotypic spectra of RUNX2 variants in CCD patients, assess their distribution across functional regions, and investigate genotype-phenotype correlations. This review included 569 reported variants and 453 CCD patients from 103 articles. Of 569 variants, in-frame variants constituted 48.68%, while null variants accounted for 51.32%. Regarding locations, RUNX2 variants were predominantly located in the RHD (55.54%), followed by PST (16.34%), NMTS (6.33%), QA (4.75%), VWRPY (1.23%), and NLS (1.41%) regions while 10.19% were in non-coding regions. In-frame variants occurred primarily in the RHD (90.97%), while null variants were found across various regions of RUNX2. Data analysis revealed a correlation between variant location and specific skeletal features in CCD patients. Missense variants, predominantly found within the functionally critical RHD, were significantly associated with supernumerary teeth, macrocephaly, metopic groove, short ribs, and hypoplastic iliac wings compared to nonsense variants. They were also significantly associated with delayed fontanelle closure, metopic synostosis, hypertelorism, limited shoulder abduction, pubic symphysis abnormalities, and hypoplastic iliac wings compared to in-frame variants found in other regions. These findings underscore the critical role of the RHD, with missense RHD variants having a more severe impact than nonsense and other in-frame variants. Additionally, in-frame insertions and deletions in RUNX2 were associated with fewer CCD features, compared to missense, frameshift, and nonsense variants. Null variants in the NLS region exhibited weaker associations with delayed fontanelle closure, supernumerary teeth, Wormian bones, and femoral head hypoplasia than variants in other regions. Moreover, the NLS variants did not consistently alter nuclear localization, questioning the role of NLS region in nuclear import. In summary, this comprehensive review significantly advances our understanding of CCD, facilitating improved phenotype-genotype correlations, enhanced clinical management, and a deeper insight into RUNX2 functional domains. This knowledge has the potential to guide the development of novel therapeutic targets for skeletal disorders.

Open article ↗



2018-05-01 | RUNX2 mutation reduces osteogenic differentiation of dental follicle cells in cleidocranial dysplasia

Disturbed permanent tooth eruption is common in cleidocranial dysplasia (CCD), a skeletal disorder caused by heterozygous mutation of RUNX2, but the mechanism underlying is still unclear. As it is well known that dental follicle cells (DFCs) play a critical role in tooth eruption, the changed biological characteristics of DFCs might give rise to disturbance of permanent tooth eruption in CCD patients. Thus, primary DFCs from one CCD patient and normal controls were collected to investigate the effect of RUNX2 mutation on the bone remodeling activity of DFCs and explore the mechanism of impaired permanent tooth eruption in this disease. Conservation and secondary structure analysis revealed that the RUNX2 mutation (c.514delT, p.172fs) found in the present CCD patient was located in the highly conserved RUNT domain and converted the structure of RUNX2. After osteogenic induction, we found that the mineralised capacity of DFCs and the expression of osteoblast-related genes, including RUNX2, ALP, OSX, OCN and Col Iα1, in DFCs was severely interfered by the RUNX2 mutation found in CCD patients. To investigate whether the osteogenic deficiency of DFCs from the CCD patient can be rescued by RUNX2 restoration, we performed 'rescue' experiments. Surprisingly, the osteogenic deficiency and the abnormal expression of osteoblast-associated genes in DFCs from the CCD patient were almost rescued by overexpression of wild-type RUNX2 using lentivirus. All these findings indicate that RUNX2 mutation can reduce the osteogenic capacity of DFCs through inhibiting osteoblast-associated genes, thereby disturbing alveolar bone formation, which serves as a motive force for tooth eruption. This effect may provide valuable explanations and implications for the mechanism of delayed permanent tooth eruption in CCD patients.

Open article ↗



2014-05-21 | Cbfβ deletion in mice recapitulates cleidocranial dysplasia and reveals multiple functions of Cbfβ required for skeletal development

The pathogenesis of cleidocranial dysplasia (CCD) as well as the specific role of core binding factor β (Cbfβ) and the Runt-related transcription factor (RUNX)/Cbfβ complex in postnatal skeletogenesis remain unclear. We demonstrate that Cbfβ ablation in osteoblast precursors, differentiating chondrocytes, osteoblasts, and odontoblasts via Osterix-Cre, results in severe craniofacial dysplasia, skeletal dysplasia, abnormal teeth, and a phenotype recapitulating the clinical features of CCD. Cbfβ(f/f)Osterix-Cre mice have fewer proliferative and hypertrophic chondrocytes, fewer osteoblasts, and almost absent trabecular bone, indicating that Cbfβ may maintain trabecular bone formation through its function in hypertrophic chondrocytes and osteoblasts. Cbfβ(f/f)Collagen, type 1, alpha 1 (Col1α1)-Cre mice show decreased bone mineralization and skeletal deformities, but no radical deformities in teeth, mandibles, or cartilage, indicating that osteoblast lineage-specific ablation of Cbfβ results in milder bone defects and less resemblance to CCD. Activating transcription factor 4 (Atf4) and Osterix protein levels in both mutant mice are dramatically reduced. ChIP assays show that Cbfβ directly associates with the promoter regions of Atf4 and Osterix. Our data further demonstrate that Cbfβ highly up-regulates the expression of Atf4 at the transcriptional regulation level. Overall, our genetic dissection approach revealed that Cbfβ plays an indispensable role in postnatal skeletal development and homeostasis in various skeletal cell types, at least partially by up-regulating the expression of Atf4 and Osterix. It also revealed that CCD may result from functional defects of the Runx2/Cbfβ heterodimeric complex in various skeletal cells. These insights into the role of Cbfβ in postnatal skeletogenesis and CCD pathogenesis may assist in the development of new therapies for CCD and osteoporosis.

Open article ↗



cell therapies
2021-11-15 | Identification of a familial cleidocranial dysplasia with a novel RUNX2 mutation and establishment of patient-derived induced pluripotent stem cells

Cleidocranial dysplasia (CCD) is an autosomal dominant hereditary disease associated with the gene RUNX2. Disease-specific induced pluripotent stem cells (iPSCs) have emerged as a useful resource to further study human hereditary diseases such as CCD. In this study, we identified a novel CCD-specific RUNX2 mutation and established iPSCs with this mutation. Biopsies were obtained from familial CCD patients and mutation analyses were performed through Sanger sequencing and next generation sequencing. CCD-specific human iPSCs (CCD-hiPSCs) were established and maintained under completely defined serum, feeder, and integration-free condition using a non-integrating replication-defective Sendai virus vector. We identified the novel mutation RUNX2_c.371C>G and successfully established CCD-hiPSCs. The CCD-hiPSCs inherited the same mutation, possessed pluripotency, and showed the ability to differentiate the three germ layers. We concluded that RUNX2_c.371C>G was likely pathogenic because our results, derived from next generation sequencing, are supported by actual clinical evidence, familial tracing, and genetic data. Thus, we concluded that hiPSCs with a novel CCD-specific RUNX2 mutation are viable as a resource for future studies on CCD.

Open article ↗



2019-09-22 | Stimulation of Human Osteoblast Differentiation in Magneto-Mechanically Actuated Ferromagnetic Fiber Networks

There is currently an interest in “active” implantable biomedical devices that include mechanical stimulation as an integral part of their design. This paper reports the experimental use of a porous scaffold made of interconnected networks of slender ferromagnetic fibers that can be actuated in vivo by an external magnetic field applying strains to in-growing cells. Such scaffolds have been previously characterized in terms of their mechanical and cellular responses. In this study, it is shown that the shape changes induced in the scaffolds can be used to promote osteogenesis in vitro. In particular, immunofluorescence, gene and protein analyses reveal that the actuated networks exhibit higher mineralization and extracellular matrix production, and express higher levels of osteocalcin, alkaline phosphatase, collagen type 1α1, runt-related transcription factor 2 and bone morphogenetic protein 2 than the static controls at the 3-week time point. The results suggest that the cells filling the inter-fiber spaces are able to sense and react to the magneto-mechanically induced strains facilitating osteogenic differentiation and maturation. This work provides evidence in support of using this approach to stimulate bone ingrowth around a device implanted in bone and can pave the way for further applications in bone tissue engineering.

Open article ↗



2019-09-15 | Stimulation of Human Osteoblast Differentiation in Magneto-Mechanically Actuated Ferromagnetic Fibre Networks

There is currently an interest in “active” implantable biomedical devices that include mechanical stimulation as an integral part of their design. This paper reports the experimental use of a porous scaffold made of interconnected networks of slender ferromagnetic fibres that can be actuated in vivo by an external magnetic field applying strains to in-growing cells. Such scaffolds have been previously characterized in terms of their mechanical and cellular responses. In this study, it is shown that the shape changes induced in the scaffolds can be used to promote osteogenesis in vitro. In particular, immunofluorescence, gene and protein analyses reveal that the actuated networks exhibit higher mineralization and extracellular matrix production, and express higher levels of osteocalcin, alkaline phosphatase, collagen type 1a1, runt-related transcription factor 2 and bone morphogenetic protein 2 than the static controls at the 3-week time point. The results suggest that the cells filling the inter-fibre spaces are able to sense and react to the magneto-mechanically induced strains facilitating osteogenic differentiation and maturation. This work provides evidence in support of using this approach to stimulate bone ingrowth around a device implanted in bone and can pave the way for further applications in bone tissue engineering.

Open article ↗



2018-01-22 | Targeted reversion of induced pluripotent stem cells from patients with human cleidocranial dysplasia improves bone regeneration in a rat calvarial bone defect model

Runt-related transcription factor 2 (RUNX2) haploinsufficiency causes cleidocranial dysplasia (CCD) which is characterized by supernumerary teeth, short stature, clavicular dysplasia, and osteoporosis. At present, as a therapeutic strategy for osteoporosis, mesenchymal stem cell (MSC) transplantation therapy is performed in addition to drug therapy. However, MSC-based therapy for osteoporosis in CCD patients is difficult due to a reduction in the ability of MSCs to differentiate into osteoblasts resulting from impaired RUNX2 function. Here, we investigated whether induced pluripotent stem cells (iPSCs) properly differentiate into osteoblasts after repairing the RUNX2 mutation in iPSCs derived from CCD patients to establish normal iPSCs, and whether engraftment of osteoblasts derived from properly reverted iPSCs results in better regeneration in immunodeficient rat calvarial bone defect models. Two cases of CCD patient-derived induced pluripotent stem cells (CCD-iPSCs) were generated using retroviral vectors (OCT3/4, SOX2, KLF4, and c-MYC) or a Sendai virus SeVdp vector (KOSM302L). Reverted iPSCs were established using programmable nucleases, clustered regularly interspaced short palindromic repeats (CRISPR)/Cas-derived RNA-guided endonucleases, to correct mutations in CCD-iPSCs. The mRNA expressions of osteoblast-specific markers were analyzed using quantitative reverse-transcriptase polymerase chain reaction. iPSCs-derived osteoblasts were transplanted into rat calvarial bone defects, and bone regeneration was evaluated using microcomputed tomography analysis and histological analysis. Mutation analysis showed that both contained nonsense mutations: one at the very beginning of exon 1 and the other at the initial position of the nuclear matrix-targeting signal. The osteoblasts derived from CCD-iPSCs (CCD-OBs) expressed low levels of several osteoblast differentiation markers, and transplantation of these osteoblasts into calvarial bone defects created in rats with severe combined immunodeficiency showed poor regeneration. However, reverted iPSCs improved the abnormal osteoblast differentiation which resulted in much better engraftment into the rat calvarial bone defect. Taken together, these results demonstrate that patient-specific iPSC technology can not only provide a useful disease model to elucidate the role of RUNX2 in osteoblastic differentiation but also raises the tantalizing prospect that reverted iPSCs might provide a practical medical treatment for CCD.

Open article ↗



2015-11-11 | Generation of cleidocranial dysplasia-specific human induced pluripotent stem cells in completely serum-, feeder-, and integration-free culture

Human pluripotent stem cells hold great promise for their practical and scientific potentials. To improve understanding of self-renewal and differentiation, we previously reported a defined serum-free medium hESF9 could generate and maintain human induced pluripotent stem cells (iPSCs) in serum- and feeder-free culture conditions using retroviral vectors. To avoid the unpredictable side effects associated with retrovirus integration, we report here the successful generation of hiPSCs from dental pulp cells with a non-integrating replication-defective and persistent Sendai virus (SeVdp) vector expressing four key reprogramming genes. We found that hESF9 medium in combination with fibronectin are effective for generating and maintaining hiPSCs with SeVdp (KOSM). Using this system, pluripotent and self-renewing hiPSCs could be easily and stably generated and propagated. With this system, we successfully generated hiPSCs from cleidocranial dysplasia (CCD) caused by a heterozygous germ-line mutation of runt-related protein2 (RUNX2), which has an important role in the differentiation of osteoblasts and maturation of chondrocytes. This is the first report of the establishment of CCD-specific iPSCs. The cartilage in the teratomas of CCD-iPSCs showed abnormalities. These CCD-iPSCs would be beneficial to clarify the molecular mechanism and for development of medical applications. Moreover, it brings new pathophysiological role of RUNX2 in the differentiation of the human chondrocytes and osteocytes.

Open article ↗



proteins
2026-05-18 | A Novel 4.2 kb deletion of the 3'UTR of RUNX2 Gene Causes Cleidocranial Dysplasia: Further Delineation of the Role of yhe 3'UTR.

Cleidocranial dysplasia is a rare autosomal dominant skeletal dysplasia. We present the first case in the literature involving a deletion of the 3'UTR of RUNX2 gene associated with a cleidocranial dysplasia spectrum disorder, along with the diagnostic odyssey that preceded the establishment of this diagnosis. We describe a female patient with a classical phenotype of cleidocranial dysplasia, followed by a clinical geneticist since the neonatal period. Whole genome sequencing revealed a suspected deletion encompassing the 3'UTR of RUNX2 gene, initially classified as a variant of uncertain significance. This deletion was subsequently confirmed using a custom-designed qPCR assay and reclassified as likely pathogenic, thus considered causative for the disease. The diagnosis of cleidocranial dysplasia due to RUNX2 gene dysfunction is supported by a clear phenotype-genotype correlation, the de novo origin of the variant, and functional studies underscoring the importance of the 3'UTR for RUNX2 gene function. Our case report provides new evidence supporting the functional significance of the 3'UTR of RUNX2 gene, whose haploinsufficiency, due to a small novel deletion of 4.2 kb, results in the classical phenotype of cleidocranial dysplasia. As well, our case illustrates that whole genome sequencing is advantageous for detecting copy number variants.

Open article ↗



2026-04-17 | Correlation of RUNX2 Variants With Craniofacial-Dental Phenotypes in Cleidocranial Dysplasia.

Cleidocranial dysplasia (CCD) is a rare RUNX2-related skeletal disorder characterized by craniofacial anomalies and skeletal Class III malocclusion. However, the relationship between RUNX2 variant type and phenotype severity remains unclear. This study aimed to evaluate the association between RUNX2 variant types and the severity of skeletal Class III malocclusion and dental anomalies in CCD. This cross-sectional study included 11 unrelated Thai CCD probands and 14 relatives who underwent exome or genome sequencing. RUNX2 variants were classified as non-truncating or truncating/structural according to ACMG-AMP criteria. Nine genetically confirmed individuals met the inclusion criteria for radiographic analysis. Craniofacial parameters and dental anomalies were assessed using lateral cephalograms and cone-beam computed tomography. Group comparisons were performed using nonparametric tests and correlation analysis. Truncating/structural variants were associated with shorter cranial base length, smaller SNA, and reduced nasolabial angles compared with non-truncating variants. The variant type correlated with these parameters. Skeletal Class III malocclusion was present in both groups, predominantly due to mandibular prognathism. No significant association was found between variant type and the burden or distribution of dental anomalies. RUNX2 variant type influences cranial base and maxillary morphology, contributing to skeletal Class III severity in CCD, whereas dental anomalies appear independent of variant type.

Open article ↗



2026-01-28 | Early prenatal detection of autosomal dominant skeletal dysplasia using first-trimester ultrasound and cell-free fetal DNA screening: three case reports

Case 1 (Family 1)A primigravida attended our fetal medicine clinic (FMC) in March 2015 at 12 weeks' gestation for firsttrimester (T1) Down syndrome screening.Ultrasound examination revealed an absent nasal bone (NB).A morphology scan at 20 weeks confirmed this finding, along with bilateral non-ossified parietal bones, 11 pairs of ribs, and shortened femur and humerus.Amniocentesis revealed a normal chromosomal microarray.The couple opted for termination of pregnancy at 22 weeks.A computed tomography babygram confirmed the ultrasound findings and also showed bilaterally absent clavicles, hinting at a diagnosis of cleidocranial dysplasia (CCD).Targeted sequencing of the RUNX2 gene on the amniotic fluid sample revealed a de novo heterozygous pathogenic missense variant, c.674G>A (p.Arg225Gln), confirming the diagnosis.Multimodal prenatal and genetic findings were illustrated in Figure 1.

Open article ↗



2025-02-25 | Cbfβ: A key regulator in skeletal stem cell differentiation, bone development, and disease.

The skeletal system comprises closely related yet functionally distinct bone and cartilage tissues, regulated by a complex network of transcriptional factors and signaling molecules. Among these, core-binding factor subunit beta (Cbfβ) emerges as a critical co-transcriptional factor that stabilizes Runx proteins, playing indispensable roles in skeletal development and homeostasis. Emerging evidence from genetic mouse models has highlighted the essential role of Cbfβ in directing the lineage commitment of mesenchymal stem cells (MSCs) and their differentiation into osteoblasts and chondrocytes. Notably, Cbfβ deficiency is strongly associated with severe skeletal dysplasia, affecting both endochondral and intramembranous ossification during embryonic and postnatal development. In this review, we synthesize recent advancements in understanding the structural and molecular functions of Cbfβ, with a particular focus on its interactions with key signaling pathways, including BMP/TGF-β, Wnt/β-catenin, Hippo/YAP, and IHH/PTHrP. These pathways converge on the Cbfβ/RUNX2 complex, which orchestrates a gene expression program essential for osteogenesis, bone formation, and cartilage development. The integration of these signaling networks ensures the precise regulation of skeletal development, remodeling, and repair. Furthermore, the successful local delivery of Cbfβ to address bone abnormalities underscores its potential as a novel therapeutic target for skeletal disorders such as cleidocranial dysplasia, osteoarthritis, and bone metastases. By elucidating the molecular mechanisms underlying Cbfβ function and its interactions with key signaling pathways, these insights not only advance our understanding of skeletal biology but also offer promising avenues for clinical intervention, ultimately improving outcomes for patients with skeletal disorders.

Open article ↗



2024-12-30 | Non-syndromic bilateral dentigerous cyst in 9-year-old boy – case report and a literature review

Dentigerous cyst is a developmental odontogenic cyst that often develops in the second and third decades of life. This is one of the most common odontogenic cyst types that involve developing, or impacted teeth, partially erupted, accounting 20% of all jaw cysts. Dentigerous cysts are usually unilateral, bilateral presentations have been associated with syndromes such as cleidocranial dysplasia and Maroteaux–Lamy syndrome. However, they can occur without any syndrome association, but are extremely rare. This article reports the case of bilateral dentigerous cysts that is non-syndromic in a 9-year-old boy.

Open article ↗



other
2023-03-21 | Induction of osteogenic differentiation of MSCs by GSK3β knockdown through GSK3β siRNAs transfection

Abstract The development of effective strategies for the treatment of bone defects is based on gene therapy methods aimed at regulating the differentiation of osteoprogenitor cells. One approach is the development of knockdown systems of inhibitory genes of osteogenic cell differentiation using siRNA molecules. In this work, we developed approaches to induce osteogenic differentiation of mesenchymal stem cells (MSCs) by knockdown of GSK3β using siRNAs in cultures of MSCs derived from human adipose tissue (AD-MSCs). For this purpose, we performed a comparative evaluation of the efficacy of lipoplexes and polyplexes formed with one of the 4 siRNA molecules and 5 commercial transfection agents most commonly used in laboratory practice. The most effective transfection agent appeared to be PEI, which demonstrated high cytocompatibility in free form and as part of polyplexes even when maximum concentrations were used. Using the polyplexes formed by siRNA molecule designed for the first time and PEI, we developed a highly efficient GSK3β gene knockdown system, which showed its effectiveness in cultures of AD-MSCs. As a result, we demonstrated the osteoinductive properties of GSK3β siRNA molecules in these cultures. The results obtained can be applied in the development of gene therapy strategies based on siRNA molecules in human bone tissue diseases.

Open article ↗



2022-09-13 | A Novel lncRNA Mediates the Delayed Tooth Eruption of Cleidocranial Dysplasia.

Delayed eruption of permanent teeth is a common symptom of cleidocranial dysplasia (CCD). Previous studies have focused on the anomaly of osteogenesis resulting from mutations in the Runt-related transcription factor-2 gene (RUNX2). However, deficiencies in osteoclastogenesis and bone resorption, and the epigenetic regulation mediated by long non-coding (lnc)RNAs in CCD remain to be elucidated. Here, a novel osteoclast-specific lncRNA (OC-lncRNA) was identified during the osteoclast differentiation of RAW 264.7 cells transfected with a RUNX2 mutation expression cassette. We further confirmed that OC-lncRNA positively regulated osteoclastogenesis and bone resorption. The OC-lncRNA promoted the expression of CXC chemokine receptor type 3 (CXCR3) by competitively binding to microRNA (miR)-221-5p. The CXCR3-CXC-motif chemokine ligand 10 (CXCL10) interaction and nuclear factor-κB constituted a positive feedback that positively regulated osteoclastogenesis and bone resorption. These results demonstrate that OC-lncRNA-mediated osteoclast dysfunction via the OC-lncRNA-miR-221-5p-CXCR3 axis, which is involved in the process of delayed tooth eruption of CCD.

Open article ↗



2018-12-03 | microRNA‐31 inhibition partially ameliorates the deficiency of bone marrow stromal cells from cleidocranial dysplasia

Abstract Background Cleidocranial dysplasia (CCD) in humans is an autosomal‐dominant skeletal dysplasia caused by heterozygous mutations of the runt‐related transcription factor 2 ( RUNX2 ) and significantly increases the risk of osteoporosis. Increasing evidence demonstrates that the dysfunction of bone marrow stromal cells from CCD patients (BMSCs‐CCD) contributes to the bone deficiency, but the characteristics of BMSCs‐CCD and the mechanisms that underlie their properties remain undefined. Methods The clinical manifestations of three CCD patients were collected and the mutations of RUNX2 were analyzed. The properties of proliferation, osteogenesis, stemness, and senescence of BMSCs‐CCD were compared with that of BMSCs from healthy donors. The expression of microRNA‐31 ( miR‐31 ) between BMSCs‐CCD and BMSCs was measured and lentivirus‐carried miR‐31 inhibitor was used to determine the role of miR‐31 in BMSCs‐CCD both in vitro and in vivo. The molecular mechanisms underlying RUNX2‐miR31 and miR‐31 targeting stemness and senescence of BMSCs‐CCD were also explored. Results We identified two mutation sites of RUNX2 via exome sequencing from 2 of 3 Chinese CCD patients with typical clinical presentations. Compared with BMSCs from healthy donors, BMSCs‐CCD displayed significantly attenuated proliferation, osteogenesis and stemness, and enhanced senescence. Meanwhile, miR‐31 knockdown could ameliorate these deficiency phenotypes of BMSCs‐CCD by regulating SATB2 , BMI1 , CDKN , and SP7 . Mechanistically, RUNX2 directly repressed miR‐31 expression, and therefore RUNX2 haploinsufficiency in CCD leading to miR‐31 upregulation contributed to the deficiency of BMSCs‐CCD. miR‐31 inhibition in BMSCs‐CCD showed enhanced osteogenesis through heterotopic subcutaneous implantation in the nude mice. Conclusions Our results show the functional deficiencies of BMSCs‐CCD and a potential role of miR‐31 in BMSCs‐CCD deficiencies. The application of miR‐31 inhibitor in BMSCs‐CCD might lend hope for developing BMSC‐based therapeutic approaches against CCD‐associated skeletal diseases.

Open article ↗



2017-12-14 | Mutant Runx2 regulates amelogenesis and osteogenesis through a miR-185-5p-Dlx2 axis

Regulation of microRNAs (miRNA) has been extensively investigated in diseases; however, little is known about the roles of miRNAs in cleidocranial dysplasia (CCD). The aim of the present study was to investigate the potential involvement of miRNAs in CCD. In vitro site-directed mutagenesis was performed to construct three mutant Runx2 expression vectors, which were then transfected into LS8 cells and MC3T3-E1 cells, to determine the impact on amelogenesis and osteogenesis, respectively. miRCURY LNA miRNA microarray identify miR-185-5p as a miRNA target commonly induced by all three Runx2 mutants. Real-time quantitative PCR was applied to determine the expression of miR-185-5p and Dlx2 in samples. Dual-luciferase reporter assays were conducted to confirm Dlx2 as a legitimate target of miR-185-5p. The suppressive effect of miR-185-5p on amelogenesis and osteogenesis of miR-185-5p was evaluated by RT-PCR and western blot examination of Amelx, Enam, Klk4, and Mmp20 gene and protein expression, and by Alizarin Red stain. We found that mutant Runx2 suppressed amelogenesis and osteogenesis. miR-185-5p, induced by Runx2, suppressed amelogenesis and osteogenesis. Furthermore, we identified Dlx2 as direct target of miR-185-5p. Consistently, Dlx2 expression was inversely correlated with miR-185-5p levels. This study highlights the molecular etiology and significance of miR-185-5p in CCD, and suggests that targeting miR-185-5p may represent a new therapeutic strategy in prevention or intervention of CCD.

Open article ↗



2017-12-09 | mmu-miR-1963 negatively regulates the ameloblast differentiation of LS8 cell line by directly targeting Smoc2 3’UTR

RUNX2 is a key regulator of osteogenic differentiation and odontoblastic differentiation. RUNX2 mutations could cause Cleidocranial dysplasia (CCD; OMIM119600), which is featured by abnormal development of bone and teeth. By using microRNA array, we identified a large number of microRNAs that showed different expression between wild-type Runx2 group and mutant groups. The aim of this study is to find out the effect of mmu-miR-1963, which was downregulated in all mutant Runx2 groups, on the ameloblast differentiation of LS8 cells. qPCR and Western Blot results showed the suppressive effect of mmu-miR-1963 on ameloblast differentiation of LS8 cell line. We further confirmed Smoc2 as one direct target of mmu-miR-1963. For the first time, we showed that mmu-miR-1963 could regulate the ameloblast differentiation of LS8 by targeting Smoc2. This study suggests the suppressive role of mmu-miR-1963 on ameloblast differentiation of LS8 via directly targeting the 3’UTR of Smoc2. We also demonstrated that Smoc2 itself could promote the ameloblast differentiation of LS8 for the first time. Our results indicate a novel explanation to the enamel hypoplasia phenotype in part of CCD patients.

Open article ↗



small molecules
2026-09-17 | SCFJFK regulates osteoblast differentiation through targeting RUNX2.

RUNX2 (Runt-related transcription factor 2) is a master regulator of osteogenesis, and its genetic mutations are associated with ~65% cases of cleidocranial dysplasia (CCD), an autosomal dominant abnormal bone development disorder in humans with defective intramembranous bone formation. However, how these mutations affect bone formation remains to be investigated. Here, we report that RUNX2 interacts with the F-box protein JFK and is destabilized by the SKP1-CUL1-JFK E3 ubiquitin ligase complex (SCFJFK). We find that several CCD-associated mutations of RUNX2 acquire an increased affinity toward SCFJFK thus an accelerated proteasomal degradation. We demonstrate that SCFJFK-mediated RUNX2 degradation suppresses osteoblast differentiation. Consistently, Jfk-null mice exhibit increased trabecular bone volume and bone mineral density and are resistant to Runx2 haploinsufficiency-induced CCD-like syndrome. Interestingly, RUNX2 binds to the JFK promoter and represses its transcription, establishing a feedback loop to promote osteoblast differentiation, and remarkably, the CCD-associated RUNX2 mutants also display an impaired transcription repression of JFK. Our study demonstrates SCFJFK as an E3 ligase for RUNX2 and uncovers a feedback regulatory loop between SCFJFK and RUNX2 that is implemented in bone development and implicated in CCD, supporting the pursuit of JFK as a potential target to ameliorate CCD-like syndrome.

Open article ↗



2026-04-20 | Sost deficiency restores calvarial bone thickness without recovery of sutural growth in Runx2 missense mutant mice.

Runt-related transcription factor 2 (Runx2) is a key transcription factor essential for osteogenesis, and RUNX2 haploinsufficiency causes cleidocranial dysplasia, whereas sclerostin encoded by Sost negatively regulates bone mass by antagonizing Wnt/β-catenin signaling. Although the individual roles of Runx2 and sclerostin in skeletal biology have been extensively studied, their combined effects on calvarial development have not been directly examined in vivo. Here, we investigated whether Sost deficiency affects the cranial phenotype associated with Runx2 haploinsufficiency. Using skeletal preparations, micro-computed tomography, and three-dimensional morphometric analysis of the interparietal bone, we analyzed Sost-deficient, Runx2 missense mutant, and Runx2-Sost compound mutant mice at embryonic day 18.5 (E18.5) and postnatal day 90 (P90). At E18.5, both Runx2R232Q/R232Q;Sost+/+ and Runx2R232Q/R232Q;SostΔ26/Δ26 mice lacked ossification throughout the body. At P90, Runx2R232Q/+;Sost+/+ mice exhibited cranial hypoplasia with delayed suture closure. In Runx2R232Q/+;SostΔ26/Δ26 mice, interparietal bone thickness was restored to wild-type levels, whereas the bone volume showed only partial recovery. Bone volume/tissue volume and bone mineral density increased to levels higher than those of wild-type, comparable to those of Runx2+/+;SostΔ26/Δ26. However, the bone surface area exhibited no significant improvement, and delayed suture closure around the interparietal bone and anterior and posterior fontanelles persisted. Thus, Sost-deficiency augments postnatal calvarial mass primarily by thickening without expanding the surface area and does not normalize suture/fontanelle morphogenesis under Runx2 haploinsufficiency. Our findings reveal a differential genetic effect of Sost deficiency on calvarial thickness and sutural growth in mice with Runx2 haploinsufficiency.

Open article ↗



2026-01-01 | Clinical and genetic study on a cleidocranial dysplasia family

Objective To confirm the mutation in a family with cleidocranial dysplasia (CCD) and explore its possible effects on protein structure and function. Methods A proband with CCD was diagnosed through clinical symptoms and radiography examinations. Peripheral blood samples were collected from the proband and his family members for whole-exome sequencing. The pathogenic mutation was validated by Sanger sequencing. Further investigations were conducted to analyze the protein structural and functional changes induced by this mutation and explore the potential mechanisms by which this gene contributed to the pathogenesis of CCD. Results In this family, both the proband and his father exhibited typical clinical manifestations of cleidocranial dysplasia (CCD), including clavicular hypoplasia, delayed closure of fontanelles, craniofacial and dental abnormalities. A previously reported RUNX2 missense mutation (c. 569G>A, p. Arg190Gln) was identified in this family. This mutation occurred within the highly conserved runt domain, disrupting RUNX2 protein function. Bioinformatics analysis further confirmed the critical role of RUNX2 in craniofacial skeleton and tooth development. Conclusion A missense mutation in exon 4 of the RUNX2 gene is identified in a Chinese CCD family, providing novel therapeutic insights for CCD patients from molecular biological perspective.

Open article ↗



2025-12-27 | Functional impact of pathogenic mutations in the Runt homology domain of mouse Runx2 on skeletal and dental phenotypes in cleidocranial dysplasia.

Runt-related transcription factor 2 (RUNX2) is essential for skeletogenesis, and mutations in its gene cause cleidocranial dysplasia (CCD), an autosomal dominant skeletal disorder. The evolutionarily conserved 128-amino acid Runt homology domain (RHD) of human RUNX2 is essential for DNA binding and heterodimerization, and serves as a mutation hotspot associated with severe CCD phenotypes. To elucidate the functional impact of pathogenic RHD mutations in vivo, we generated two novel mouse lines: one carrying a missense mutation, c.695G>A, p.Arg232Gln (p.R232Q), corresponding to the human RUNX2 c.674G>A, p.Arg225Gln (p.R225Q), and the other harboring a frameshift mutation, c.697_698delGA, p.Glu233Thrfs*9 (p.E233Tfs*9), causing a premature stop codon. Homozygous Runx2R232Q/R232Q and Runx2E233Tfs*9/E233Tfs*9 mice lacked membranous ossification, whereas heterozygous Runx2R232Q/+ and Runx2E233Tfs*9/+ mice displayed typical CCD-like skeletal features, including an open anterior fontanelle and clavicle hypoplasia. Unexpectedly, heterozygotes carrying pathogenic RHD mutations developed small root-like protrusions, mostly one but rarely two, at the pulp chamber floor of three-rooted maxillary first molars during furcation, revealing a previously unrecognized dental phenotype. Dual luciferase assays showed that p.R232Q almost completely lost transactivation of the osteocalcin enhancer/promoter. Immunostaining showed that wild-type Runx2 was robustly expressed in osteoblasts and hypertrophic chondrocytes during bone formation, while the p.R232Q mutant Runx2 in Runx2R232Q/R232Q mice exhibited reduced expression in hypertrophic chondrocytes and partially impaired nuclear localization. These abnormalities led to defective osteoblast differentiation and chondrocyte maturation. Thus, our mutant mouse model provides a valuable in vivo platform to study CCD pathogenesis, mechanisms of tooth root furcation, and therapeutic interventions targeting dysfunctional RHD.

Open article ↗



2025-05-30 | RUNX2 is essential for maintaining synchondrosis chondrocytes and cranial base growth.

The cranial base synchondroses, comprised of opposite-facing bidirectional chondrocyte layers, drive anteroposterior cranial base growth. In humans, RUNX2 haploinsufficiency causes cleidocranial dysplasia associated with deficient midfacial growth. However, how RUNX2 regulates chondrocytes in the cranial base synchondroses remains unknown. To address this, we inactivated Runx2 in postnatal synchondrosis chondrocytes using a tamoxifen-inducible Fgfr3-creER (Fgfr3-Runx2cKO) mouse model. Fgfr3-Runx2cKO mice displayed skeletal dwarfism and reduced anteroposterior cranial base growth associated with premature synchondrosis ossification due to impaired chondrocyte proliferation, accelerated hypertrophy, apoptosis, and osteoclast-mediated cartilage resorption. Lineage tracing reveals that Runx2-deficient Fgfr3+ cells failed to differentiate into osteoblasts. Notably, Runx2-deficient chondrocytes showed an elevated level of FGFR3 and its downstream signaling components, pERK1/2 and SOX9, suggesting that RUNX2 downregulates FGFR3 in the synchondrosis. This study unveils a new role of Runx2 in cranial base chondrocytes, identifying a possible RUNX2-FGFR3-MAPK-SOX9 signaling axis that may control cranial base growth.

Open article ↗



gene therapies
2025-06-21 | Functional impact of pathogenic Runt domain mutations in Runx2 on skeletal and dental development in cleidocranial dysplasia

Abstract Runt-related transcription factor 2 (RUNX2) is essential for skeletogenesis, and mutations in its gene cause cleidocranial dysplasia (CCD), an autosomal dominant skeletal disorder. The evolutionarily conserved 128-amino acid Runt homology domain (RHD) of human RUNX2 is essential for DNA binding and heterodimerization, and serves as a mutation hotspot associated with severe CCD phenotypes. To elucidate the functional impact of pathogenic RHD mutations in vivo , we generated two novel mouse lines: one carrying a missense mutation, c.695G>A (p.R232Q) ( Runx2 m/+ ), corresponding to the human RUNX2 c.674G>A (p.R225Q), and the other harboring a frameshift mutation, c.697_698delGA (p.E233TfsTer9) ( Runx2 112/+ ), causing a premature stop codon. Homozygous Runx2 m/m and Runx2 112/112 mice lacked membranous ossification, whereas heterozygous Runx2 m/+ and Runx2 112/+ mice displayed typical CCD-like skeletal features, including an open anterior fontanelle and clavicle hypoplasia. Unexpectedly, heterozygotes carrying pathogenic mutations in RHD developed an accessory root-like protrusion at the furcation of three-rooted maxillary first molars, representing a previously unrecognized dental phenotype during root development. Dual luciferase assays revealed impaired transactivation of the p.R232Q mutant Runx2 on the osteocalcin enhancer/promoter. Wild-type Runx2 was robustly expressed in osteoblasts and hypertrophic chondrocytes during bone formation, but the mutant Runx2 exhibited reduced expression in hypertrophic chondrocytes and partially impaired nuclear localization, resulting in arrested osteoblast and chondrocyte maturation. Our mutant mouse model provides a valuable in vivo platform to study CCD pathogenesis, mechanisms of tooth root furcation, and therapeutic interventions targeting dysfunctional RHD.

Open article ↗



2025-04-10 | Downregulation of Nesprin1 by Runx2 deficiency is critical for the development of skeletal laminopathy-like pathology.

Runx2 is a master regulator of bone formation, and its dysfunction causes cleidocranial dysplasia (CCD) in humans. When iPS cells were generated from patients with CCD and Runx2-deficient iPS cells were generated using gene-editing techniques, abnormal laminopathy-like nuclei were observed. Runx2-deficient cells showed reduced Lamin A/C expression, but not protein levels. However, in Runx2-deficient cells, both the gene expression and protein levels of Nesprin1 were reduced, perinuclear actin fibers were sparser, and nuclear stiffness was reduced. Forced expression of Lamin A/C increased nuclear stiffness but did not improve nuclear morphology. In contrast, the induction of Nesprin1 expression alone normalized nuclear stiffness and restored nuclear morphology and perinuclear actin distribution. In Runx2-null cells, mechanical stress-induced phosphorylation of emerin was not observed. In contrast, forced expression of Nesprin1 in Runx2-null cells resulted in phosphorylation of emerin, indicating the restoration of intracellular tension. These observations were confirmed by atomic force microscopy. Therefore, the intracellular tension was inferred to pull the nuclear membrane into its normal shape. CUT&RUN assay and single RNA-seq analysis showed that an aberrant nuclear membrane caused loss of nuclear lamina gene regulation machinery, making the progression of normal osteogenic differentiation impossible; however, supplementation with Nesprin1 restored gene regulation mechanisms and promoted preosteoblast formation with normal nuclear morphology. Nesprin1 expression induced by Runx2 is essential for epigenetic regulation of the nuclear lamina. We propose CCD as a type of laminopathy involving defective expression of Nesprin1 regulated by Runx2.

Open article ↗



2024-12-04 | The impact of RUNX2 gene variants on cleidocranial dysplasia phenotype: a systematic review.

Cleidocranial Dysplasia (CCD) is a rare genetic disorder characterized by skeletal abnormalities and dental anomalies, primarily caused by variants in the RUNX2 gene. Understanding the spectrum of RUNX2 variants and their effects on CCD phenotypes is crucial for accurate diagnosis and management strategies. This systematic review aimed to comprehensively analyze the genotypic and phenotypic spectra of RUNX2 variants in CCD patients, assess their distribution across functional regions, and investigate genotype-phenotype correlations. This review included 569 reported variants and 453 CCD patients from 103 articles. Of 569 variants, in-frame variants constituted 48.68%, while null variants accounted for 51.32%. Regarding locations, RUNX2 variants were predominantly located in the RHD (55.54%), followed by PST (16.34%), NMTS (6.33%), QA (4.75%), VWRPY (1.23%), and NLS (1.41%) regions while 10.19% were in non-coding regions. In-frame variants occurred primarily in the RHD (90.97%), while null variants were found across various regions of RUNX2. Data analysis revealed a correlation between variant location and specific skeletal features in CCD patients. Missense variants, predominantly found within the functionally critical RHD, were significantly associated with supernumerary teeth, macrocephaly, metopic groove, short ribs, and hypoplastic iliac wings compared to nonsense variants. They were also significantly associated with delayed fontanelle closure, metopic synostosis, hypertelorism, limited shoulder abduction, pubic symphysis abnormalities, and hypoplastic iliac wings compared to in-frame variants found in other regions. These findings underscore the critical role of the RHD, with missense RHD variants having a more severe impact than nonsense and other in-frame variants. Additionally, in-frame insertions and deletions in RUNX2 were associated with fewer CCD features, compared to missense, frameshift, and nonsense variants. Null variants in the NLS region exhibited weaker associations with delayed fontanelle closure, supernumerary teeth, Wormian bones, and femoral head hypoplasia than variants in other regions. Moreover, the NLS variants did not consistently alter nuclear localization, questioning the role of NLS region in nuclear import. In summary, this comprehensive review significantly advances our understanding of CCD, facilitating improved phenotype-genotype correlations, enhanced clinical management, and a deeper insight into RUNX2 functional domains. This knowledge has the potential to guide the development of novel therapeutic targets for skeletal disorders.

Open article ↗



2018-05-01 | RUNX2 mutation reduces osteogenic differentiation of dental follicle cells in cleidocranial dysplasia

Disturbed permanent tooth eruption is common in cleidocranial dysplasia (CCD), a skeletal disorder caused by heterozygous mutation of RUNX2, but the mechanism underlying is still unclear. As it is well known that dental follicle cells (DFCs) play a critical role in tooth eruption, the changed biological characteristics of DFCs might give rise to disturbance of permanent tooth eruption in CCD patients. Thus, primary DFCs from one CCD patient and normal controls were collected to investigate the effect of RUNX2 mutation on the bone remodeling activity of DFCs and explore the mechanism of impaired permanent tooth eruption in this disease. Conservation and secondary structure analysis revealed that the RUNX2 mutation (c.514delT, p.172fs) found in the present CCD patient was located in the highly conserved RUNT domain and converted the structure of RUNX2. After osteogenic induction, we found that the mineralised capacity of DFCs and the expression of osteoblast-related genes, including RUNX2, ALP, OSX, OCN and Col Iα1, in DFCs was severely interfered by the RUNX2 mutation found in CCD patients. To investigate whether the osteogenic deficiency of DFCs from the CCD patient can be rescued by RUNX2 restoration, we performed 'rescue' experiments. Surprisingly, the osteogenic deficiency and the abnormal expression of osteoblast-associated genes in DFCs from the CCD patient were almost rescued by overexpression of wild-type RUNX2 using lentivirus. All these findings indicate that RUNX2 mutation can reduce the osteogenic capacity of DFCs through inhibiting osteoblast-associated genes, thereby disturbing alveolar bone formation, which serves as a motive force for tooth eruption. This effect may provide valuable explanations and implications for the mechanism of delayed permanent tooth eruption in CCD patients.

Open article ↗



2014-05-21 | Cbfβ deletion in mice recapitulates cleidocranial dysplasia and reveals multiple functions of Cbfβ required for skeletal development

The pathogenesis of cleidocranial dysplasia (CCD) as well as the specific role of core binding factor β (Cbfβ) and the Runt-related transcription factor (RUNX)/Cbfβ complex in postnatal skeletogenesis remain unclear. We demonstrate that Cbfβ ablation in osteoblast precursors, differentiating chondrocytes, osteoblasts, and odontoblasts via Osterix-Cre, results in severe craniofacial dysplasia, skeletal dysplasia, abnormal teeth, and a phenotype recapitulating the clinical features of CCD. Cbfβ(f/f)Osterix-Cre mice have fewer proliferative and hypertrophic chondrocytes, fewer osteoblasts, and almost absent trabecular bone, indicating that Cbfβ may maintain trabecular bone formation through its function in hypertrophic chondrocytes and osteoblasts. Cbfβ(f/f)Collagen, type 1, alpha 1 (Col1α1)-Cre mice show decreased bone mineralization and skeletal deformities, but no radical deformities in teeth, mandibles, or cartilage, indicating that osteoblast lineage-specific ablation of Cbfβ results in milder bone defects and less resemblance to CCD. Activating transcription factor 4 (Atf4) and Osterix protein levels in both mutant mice are dramatically reduced. ChIP assays show that Cbfβ directly associates with the promoter regions of Atf4 and Osterix. Our data further demonstrate that Cbfβ highly up-regulates the expression of Atf4 at the transcriptional regulation level. Overall, our genetic dissection approach revealed that Cbfβ plays an indispensable role in postnatal skeletal development and homeostasis in various skeletal cell types, at least partially by up-regulating the expression of Atf4 and Osterix. It also revealed that CCD may result from functional defects of the Runx2/Cbfβ heterodimeric complex in various skeletal cells. These insights into the role of Cbfβ in postnatal skeletogenesis and CCD pathogenesis may assist in the development of new therapies for CCD and osteoporosis.

Open article ↗



cell therapies
2021-11-15 | Identification of a familial cleidocranial dysplasia with a novel RUNX2 mutation and establishment of patient-derived induced pluripotent stem cells

Cleidocranial dysplasia (CCD) is an autosomal dominant hereditary disease associated with the gene RUNX2. Disease-specific induced pluripotent stem cells (iPSCs) have emerged as a useful resource to further study human hereditary diseases such as CCD. In this study, we identified a novel CCD-specific RUNX2 mutation and established iPSCs with this mutation. Biopsies were obtained from familial CCD patients and mutation analyses were performed through Sanger sequencing and next generation sequencing. CCD-specific human iPSCs (CCD-hiPSCs) were established and maintained under completely defined serum, feeder, and integration-free condition using a non-integrating replication-defective Sendai virus vector. We identified the novel mutation RUNX2_c.371C>G and successfully established CCD-hiPSCs. The CCD-hiPSCs inherited the same mutation, possessed pluripotency, and showed the ability to differentiate the three germ layers. We concluded that RUNX2_c.371C>G was likely pathogenic because our results, derived from next generation sequencing, are supported by actual clinical evidence, familial tracing, and genetic data. Thus, we concluded that hiPSCs with a novel CCD-specific RUNX2 mutation are viable as a resource for future studies on CCD.

Open article ↗



2019-09-22 | Stimulation of Human Osteoblast Differentiation in Magneto-Mechanically Actuated Ferromagnetic Fiber Networks

There is currently an interest in “active” implantable biomedical devices that include mechanical stimulation as an integral part of their design. This paper reports the experimental use of a porous scaffold made of interconnected networks of slender ferromagnetic fibers that can be actuated in vivo by an external magnetic field applying strains to in-growing cells. Such scaffolds have been previously characterized in terms of their mechanical and cellular responses. In this study, it is shown that the shape changes induced in the scaffolds can be used to promote osteogenesis in vitro. In particular, immunofluorescence, gene and protein analyses reveal that the actuated networks exhibit higher mineralization and extracellular matrix production, and express higher levels of osteocalcin, alkaline phosphatase, collagen type 1α1, runt-related transcription factor 2 and bone morphogenetic protein 2 than the static controls at the 3-week time point. The results suggest that the cells filling the inter-fiber spaces are able to sense and react to the magneto-mechanically induced strains facilitating osteogenic differentiation and maturation. This work provides evidence in support of using this approach to stimulate bone ingrowth around a device implanted in bone and can pave the way for further applications in bone tissue engineering.

Open article ↗



2019-09-15 | Stimulation of Human Osteoblast Differentiation in Magneto-Mechanically Actuated Ferromagnetic Fibre Networks

There is currently an interest in “active” implantable biomedical devices that include mechanical stimulation as an integral part of their design. This paper reports the experimental use of a porous scaffold made of interconnected networks of slender ferromagnetic fibres that can be actuated in vivo by an external magnetic field applying strains to in-growing cells. Such scaffolds have been previously characterized in terms of their mechanical and cellular responses. In this study, it is shown that the shape changes induced in the scaffolds can be used to promote osteogenesis in vitro. In particular, immunofluorescence, gene and protein analyses reveal that the actuated networks exhibit higher mineralization and extracellular matrix production, and express higher levels of osteocalcin, alkaline phosphatase, collagen type 1a1, runt-related transcription factor 2 and bone morphogenetic protein 2 than the static controls at the 3-week time point. The results suggest that the cells filling the inter-fibre spaces are able to sense and react to the magneto-mechanically induced strains facilitating osteogenic differentiation and maturation. This work provides evidence in support of using this approach to stimulate bone ingrowth around a device implanted in bone and can pave the way for further applications in bone tissue engineering.

Open article ↗



2018-01-22 | Targeted reversion of induced pluripotent stem cells from patients with human cleidocranial dysplasia improves bone regeneration in a rat calvarial bone defect model

Runt-related transcription factor 2 (RUNX2) haploinsufficiency causes cleidocranial dysplasia (CCD) which is characterized by supernumerary teeth, short stature, clavicular dysplasia, and osteoporosis. At present, as a therapeutic strategy for osteoporosis, mesenchymal stem cell (MSC) transplantation therapy is performed in addition to drug therapy. However, MSC-based therapy for osteoporosis in CCD patients is difficult due to a reduction in the ability of MSCs to differentiate into osteoblasts resulting from impaired RUNX2 function. Here, we investigated whether induced pluripotent stem cells (iPSCs) properly differentiate into osteoblasts after repairing the RUNX2 mutation in iPSCs derived from CCD patients to establish normal iPSCs, and whether engraftment of osteoblasts derived from properly reverted iPSCs results in better regeneration in immunodeficient rat calvarial bone defect models. Two cases of CCD patient-derived induced pluripotent stem cells (CCD-iPSCs) were generated using retroviral vectors (OCT3/4, SOX2, KLF4, and c-MYC) or a Sendai virus SeVdp vector (KOSM302L). Reverted iPSCs were established using programmable nucleases, clustered regularly interspaced short palindromic repeats (CRISPR)/Cas-derived RNA-guided endonucleases, to correct mutations in CCD-iPSCs. The mRNA expressions of osteoblast-specific markers were analyzed using quantitative reverse-transcriptase polymerase chain reaction. iPSCs-derived osteoblasts were transplanted into rat calvarial bone defects, and bone regeneration was evaluated using microcomputed tomography analysis and histological analysis. Mutation analysis showed that both contained nonsense mutations: one at the very beginning of exon 1 and the other at the initial position of the nuclear matrix-targeting signal. The osteoblasts derived from CCD-iPSCs (CCD-OBs) expressed low levels of several osteoblast differentiation markers, and transplantation of these osteoblasts into calvarial bone defects created in rats with severe combined immunodeficiency showed poor regeneration. However, reverted iPSCs improved the abnormal osteoblast differentiation which resulted in much better engraftment into the rat calvarial bone defect. Taken together, these results demonstrate that patient-specific iPSC technology can not only provide a useful disease model to elucidate the role of RUNX2 in osteoblastic differentiation but also raises the tantalizing prospect that reverted iPSCs might provide a practical medical treatment for CCD.

Open article ↗



2015-11-11 | Generation of cleidocranial dysplasia-specific human induced pluripotent stem cells in completely serum-, feeder-, and integration-free culture

Human pluripotent stem cells hold great promise for their practical and scientific potentials. To improve understanding of self-renewal and differentiation, we previously reported a defined serum-free medium hESF9 could generate and maintain human induced pluripotent stem cells (iPSCs) in serum- and feeder-free culture conditions using retroviral vectors. To avoid the unpredictable side effects associated with retrovirus integration, we report here the successful generation of hiPSCs from dental pulp cells with a non-integrating replication-defective and persistent Sendai virus (SeVdp) vector expressing four key reprogramming genes. We found that hESF9 medium in combination with fibronectin are effective for generating and maintaining hiPSCs with SeVdp (KOSM). Using this system, pluripotent and self-renewing hiPSCs could be easily and stably generated and propagated. With this system, we successfully generated hiPSCs from cleidocranial dysplasia (CCD) caused by a heterozygous germ-line mutation of runt-related protein2 (RUNX2), which has an important role in the differentiation of osteoblasts and maturation of chondrocytes. This is the first report of the establishment of CCD-specific iPSCs. The cartilage in the teratomas of CCD-iPSCs showed abnormalities. These CCD-iPSCs would be beneficial to clarify the molecular mechanism and for development of medical applications. Moreover, it brings new pathophysiological role of RUNX2 in the differentiation of the human chondrocytes and osteocytes.

Open article ↗



proteins
2026-05-18 | A Novel 4.2 kb deletion of the 3'UTR of RUNX2 Gene Causes Cleidocranial Dysplasia: Further Delineation of the Role of yhe 3'UTR.

Cleidocranial dysplasia is a rare autosomal dominant skeletal dysplasia. We present the first case in the literature involving a deletion of the 3'UTR of RUNX2 gene associated with a cleidocranial dysplasia spectrum disorder, along with the diagnostic odyssey that preceded the establishment of this diagnosis. We describe a female patient with a classical phenotype of cleidocranial dysplasia, followed by a clinical geneticist since the neonatal period. Whole genome sequencing revealed a suspected deletion encompassing the 3'UTR of RUNX2 gene, initially classified as a variant of uncertain significance. This deletion was subsequently confirmed using a custom-designed qPCR assay and reclassified as likely pathogenic, thus considered causative for the disease. The diagnosis of cleidocranial dysplasia due to RUNX2 gene dysfunction is supported by a clear phenotype-genotype correlation, the de novo origin of the variant, and functional studies underscoring the importance of the 3'UTR for RUNX2 gene function. Our case report provides new evidence supporting the functional significance of the 3'UTR of RUNX2 gene, whose haploinsufficiency, due to a small novel deletion of 4.2 kb, results in the classical phenotype of cleidocranial dysplasia. As well, our case illustrates that whole genome sequencing is advantageous for detecting copy number variants.

Open article ↗



2026-04-17 | Correlation of RUNX2 Variants With Craniofacial-Dental Phenotypes in Cleidocranial Dysplasia.

Cleidocranial dysplasia (CCD) is a rare RUNX2-related skeletal disorder characterized by craniofacial anomalies and skeletal Class III malocclusion. However, the relationship between RUNX2 variant type and phenotype severity remains unclear. This study aimed to evaluate the association between RUNX2 variant types and the severity of skeletal Class III malocclusion and dental anomalies in CCD. This cross-sectional study included 11 unrelated Thai CCD probands and 14 relatives who underwent exome or genome sequencing. RUNX2 variants were classified as non-truncating or truncating/structural according to ACMG-AMP criteria. Nine genetically confirmed individuals met the inclusion criteria for radiographic analysis. Craniofacial parameters and dental anomalies were assessed using lateral cephalograms and cone-beam computed tomography. Group comparisons were performed using nonparametric tests and correlation analysis. Truncating/structural variants were associated with shorter cranial base length, smaller SNA, and reduced nasolabial angles compared with non-truncating variants. The variant type correlated with these parameters. Skeletal Class III malocclusion was present in both groups, predominantly due to mandibular prognathism. No significant association was found between variant type and the burden or distribution of dental anomalies. RUNX2 variant type influences cranial base and maxillary morphology, contributing to skeletal Class III severity in CCD, whereas dental anomalies appear independent of variant type.

Open article ↗



2026-01-28 | Early prenatal detection of autosomal dominant skeletal dysplasia using first-trimester ultrasound and cell-free fetal DNA screening: three case reports

Case 1 (Family 1)A primigravida attended our fetal medicine clinic (FMC) in March 2015 at 12 weeks' gestation for firsttrimester (T1) Down syndrome screening.Ultrasound examination revealed an absent nasal bone (NB).A morphology scan at 20 weeks confirmed this finding, along with bilateral non-ossified parietal bones, 11 pairs of ribs, and shortened femur and humerus.Amniocentesis revealed a normal chromosomal microarray.The couple opted for termination of pregnancy at 22 weeks.A computed tomography babygram confirmed the ultrasound findings and also showed bilaterally absent clavicles, hinting at a diagnosis of cleidocranial dysplasia (CCD).Targeted sequencing of the RUNX2 gene on the amniotic fluid sample revealed a de novo heterozygous pathogenic missense variant, c.674G>A (p.Arg225Gln), confirming the diagnosis.Multimodal prenatal and genetic findings were illustrated in Figure 1.

Open article ↗



2025-02-25 | Cbfβ: A key regulator in skeletal stem cell differentiation, bone development, and disease.

The skeletal system comprises closely related yet functionally distinct bone and cartilage tissues, regulated by a complex network of transcriptional factors and signaling molecules. Among these, core-binding factor subunit beta (Cbfβ) emerges as a critical co-transcriptional factor that stabilizes Runx proteins, playing indispensable roles in skeletal development and homeostasis. Emerging evidence from genetic mouse models has highlighted the essential role of Cbfβ in directing the lineage commitment of mesenchymal stem cells (MSCs) and their differentiation into osteoblasts and chondrocytes. Notably, Cbfβ deficiency is strongly associated with severe skeletal dysplasia, affecting both endochondral and intramembranous ossification during embryonic and postnatal development. In this review, we synthesize recent advancements in understanding the structural and molecular functions of Cbfβ, with a particular focus on its interactions with key signaling pathways, including BMP/TGF-β, Wnt/β-catenin, Hippo/YAP, and IHH/PTHrP. These pathways converge on the Cbfβ/RUNX2 complex, which orchestrates a gene expression program essential for osteogenesis, bone formation, and cartilage development. The integration of these signaling networks ensures the precise regulation of skeletal development, remodeling, and repair. Furthermore, the successful local delivery of Cbfβ to address bone abnormalities underscores its potential as a novel therapeutic target for skeletal disorders such as cleidocranial dysplasia, osteoarthritis, and bone metastases. By elucidating the molecular mechanisms underlying Cbfβ function and its interactions with key signaling pathways, these insights not only advance our understanding of skeletal biology but also offer promising avenues for clinical intervention, ultimately improving outcomes for patients with skeletal disorders.

Open article ↗



2024-12-30 | Non-syndromic bilateral dentigerous cyst in 9-year-old boy – case report and a literature review

Dentigerous cyst is a developmental odontogenic cyst that often develops in the second and third decades of life. This is one of the most common odontogenic cyst types that involve developing, or impacted teeth, partially erupted, accounting 20% of all jaw cysts. Dentigerous cysts are usually unilateral, bilateral presentations have been associated with syndromes such as cleidocranial dysplasia and Maroteaux–Lamy syndrome. However, they can occur without any syndrome association, but are extremely rare. This article reports the case of bilateral dentigerous cysts that is non-syndromic in a 9-year-old boy.

Open article ↗



other
2023-03-21 | Induction of osteogenic differentiation of MSCs by GSK3β knockdown through GSK3β siRNAs transfection

Abstract The development of effective strategies for the treatment of bone defects is based on gene therapy methods aimed at regulating the differentiation of osteoprogenitor cells. One approach is the development of knockdown systems of inhibitory genes of osteogenic cell differentiation using siRNA molecules. In this work, we developed approaches to induce osteogenic differentiation of mesenchymal stem cells (MSCs) by knockdown of GSK3β using siRNAs in cultures of MSCs derived from human adipose tissue (AD-MSCs). For this purpose, we performed a comparative evaluation of the efficacy of lipoplexes and polyplexes formed with one of the 4 siRNA molecules and 5 commercial transfection agents most commonly used in laboratory practice. The most effective transfection agent appeared to be PEI, which demonstrated high cytocompatibility in free form and as part of polyplexes even when maximum concentrations were used. Using the polyplexes formed by siRNA molecule designed for the first time and PEI, we developed a highly efficient GSK3β gene knockdown system, which showed its effectiveness in cultures of AD-MSCs. As a result, we demonstrated the osteoinductive properties of GSK3β siRNA molecules in these cultures. The results obtained can be applied in the development of gene therapy strategies based on siRNA molecules in human bone tissue diseases.

Open article ↗



2022-09-13 | A Novel lncRNA Mediates the Delayed Tooth Eruption of Cleidocranial Dysplasia.

Delayed eruption of permanent teeth is a common symptom of cleidocranial dysplasia (CCD). Previous studies have focused on the anomaly of osteogenesis resulting from mutations in the Runt-related transcription factor-2 gene (RUNX2). However, deficiencies in osteoclastogenesis and bone resorption, and the epigenetic regulation mediated by long non-coding (lnc)RNAs in CCD remain to be elucidated. Here, a novel osteoclast-specific lncRNA (OC-lncRNA) was identified during the osteoclast differentiation of RAW 264.7 cells transfected with a RUNX2 mutation expression cassette. We further confirmed that OC-lncRNA positively regulated osteoclastogenesis and bone resorption. The OC-lncRNA promoted the expression of CXC chemokine receptor type 3 (CXCR3) by competitively binding to microRNA (miR)-221-5p. The CXCR3-CXC-motif chemokine ligand 10 (CXCL10) interaction and nuclear factor-κB constituted a positive feedback that positively regulated osteoclastogenesis and bone resorption. These results demonstrate that OC-lncRNA-mediated osteoclast dysfunction via the OC-lncRNA-miR-221-5p-CXCR3 axis, which is involved in the process of delayed tooth eruption of CCD.

Open article ↗



2018-12-03 | microRNA‐31 inhibition partially ameliorates the deficiency of bone marrow stromal cells from cleidocranial dysplasia

Abstract Background Cleidocranial dysplasia (CCD) in humans is an autosomal‐dominant skeletal dysplasia caused by heterozygous mutations of the runt‐related transcription factor 2 ( RUNX2 ) and significantly increases the risk of osteoporosis. Increasing evidence demonstrates that the dysfunction of bone marrow stromal cells from CCD patients (BMSCs‐CCD) contributes to the bone deficiency, but the characteristics of BMSCs‐CCD and the mechanisms that underlie their properties remain undefined. Methods The clinical manifestations of three CCD patients were collected and the mutations of RUNX2 were analyzed. The properties of proliferation, osteogenesis, stemness, and senescence of BMSCs‐CCD were compared with that of BMSCs from healthy donors. The expression of microRNA‐31 ( miR‐31 ) between BMSCs‐CCD and BMSCs was measured and lentivirus‐carried miR‐31 inhibitor was used to determine the role of miR‐31 in BMSCs‐CCD both in vitro and in vivo. The molecular mechanisms underlying RUNX2‐miR31 and miR‐31 targeting stemness and senescence of BMSCs‐CCD were also explored. Results We identified two mutation sites of RUNX2 via exome sequencing from 2 of 3 Chinese CCD patients with typical clinical presentations. Compared with BMSCs from healthy donors, BMSCs‐CCD displayed significantly attenuated proliferation, osteogenesis and stemness, and enhanced senescence. Meanwhile, miR‐31 knockdown could ameliorate these deficiency phenotypes of BMSCs‐CCD by regulating SATB2 , BMI1 , CDKN , and SP7 . Mechanistically, RUNX2 directly repressed miR‐31 expression, and therefore RUNX2 haploinsufficiency in CCD leading to miR‐31 upregulation contributed to the deficiency of BMSCs‐CCD. miR‐31 inhibition in BMSCs‐CCD showed enhanced osteogenesis through heterotopic subcutaneous implantation in the nude mice. Conclusions Our results show the functional deficiencies of BMSCs‐CCD and a potential role of miR‐31 in BMSCs‐CCD deficiencies. The application of miR‐31 inhibitor in BMSCs‐CCD might lend hope for developing BMSC‐based therapeutic approaches against CCD‐associated skeletal diseases.

Open article ↗



2017-12-14 | Mutant Runx2 regulates amelogenesis and osteogenesis through a miR-185-5p-Dlx2 axis

Regulation of microRNAs (miRNA) has been extensively investigated in diseases; however, little is known about the roles of miRNAs in cleidocranial dysplasia (CCD). The aim of the present study was to investigate the potential involvement of miRNAs in CCD. In vitro site-directed mutagenesis was performed to construct three mutant Runx2 expression vectors, which were then transfected into LS8 cells and MC3T3-E1 cells, to determine the impact on amelogenesis and osteogenesis, respectively. miRCURY LNA miRNA microarray identify miR-185-5p as a miRNA target commonly induced by all three Runx2 mutants. Real-time quantitative PCR was applied to determine the expression of miR-185-5p and Dlx2 in samples. Dual-luciferase reporter assays were conducted to confirm Dlx2 as a legitimate target of miR-185-5p. The suppressive effect of miR-185-5p on amelogenesis and osteogenesis of miR-185-5p was evaluated by RT-PCR and western blot examination of Amelx, Enam, Klk4, and Mmp20 gene and protein expression, and by Alizarin Red stain. We found that mutant Runx2 suppressed amelogenesis and osteogenesis. miR-185-5p, induced by Runx2, suppressed amelogenesis and osteogenesis. Furthermore, we identified Dlx2 as direct target of miR-185-5p. Consistently, Dlx2 expression was inversely correlated with miR-185-5p levels. This study highlights the molecular etiology and significance of miR-185-5p in CCD, and suggests that targeting miR-185-5p may represent a new therapeutic strategy in prevention or intervention of CCD.

Open article ↗



2017-12-09 | mmu-miR-1963 negatively regulates the ameloblast differentiation of LS8 cell line by directly targeting Smoc2 3’UTR

RUNX2 is a key regulator of osteogenic differentiation and odontoblastic differentiation. RUNX2 mutations could cause Cleidocranial dysplasia (CCD; OMIM119600), which is featured by abnormal development of bone and teeth. By using microRNA array, we identified a large number of microRNAs that showed different expression between wild-type Runx2 group and mutant groups. The aim of this study is to find out the effect of mmu-miR-1963, which was downregulated in all mutant Runx2 groups, on the ameloblast differentiation of LS8 cells. qPCR and Western Blot results showed the suppressive effect of mmu-miR-1963 on ameloblast differentiation of LS8 cell line. We further confirmed Smoc2 as one direct target of mmu-miR-1963. For the first time, we showed that mmu-miR-1963 could regulate the ameloblast differentiation of LS8 by targeting Smoc2. This study suggests the suppressive role of mmu-miR-1963 on ameloblast differentiation of LS8 via directly targeting the 3’UTR of Smoc2. We also demonstrated that Smoc2 itself could promote the ameloblast differentiation of LS8 for the first time. Our results indicate a novel explanation to the enamel hypoplasia phenotype in part of CCD patients.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.